Market Newsdesk

CHARLOTTE, N.C., Sept. 29, 2022 (GLOBE NEWSWIRE) — Strong Technical Services “(STS”), a wholly-owned subsidiary of Ballantyne Strong, Inc. (NYSE American: BTN) (“Ballantyne” or the “Company”), today announced that it has initiated a new digital content delivery offering for its cinema partners. Built on the Google Cloud global network, the offering enables STS customers to upload and distribute content from one convenient digital feed rather than downloading content files from multiple file-hosting services. Content can also be placed directly on the customer’s TMS from the service.

“We are committed to helping our cinema partners streamline their operations and this upgraded technology drives efficiencies by providing one seamless content delivery option rather than the retrieval of content from different sources,” commented Ray Boegner, President of Strong Entertainment at Ballantyne Strong. “STS has led the way on many innovative technologies in the cinema services industry and we’re pleased to diversify our portfolio with the addition of digital content delivery. We are rolling this out to one of our exhibitor partners after successfully piloting at 20 locations and are now offering it to our broader customer base.”

About Ballantyne Strong, Inc. and Strong Technical Services, Inc.

Ballantyne Strong, Inc. is a diversified holding company with operations and investments across a broad range of industries. The Company’s Strong Entertainment business unit includes STRONG/MDI Screen Systems (www.strongmdi.com), the leading premium screen and projection coatings supplier in the world and Strong Technical Services (www.strong-tech.com), which provides comprehensive managed service offerings with 24/7/365 support nationwide to ensure solution uptime and availability. Ballantyne Strong also holds stakes in GreenFirst Forest Products Inc., Firefly, Inc, and FG Financial Group, Inc.

Forward-Looking Statements

In addition to the historical information included herein, this press release includes forward-looking statements, such as management’s expectations regarding its portfolio companies, the Company’s intent to pursue an initial public offering and separate listing of its Entertainment business, as well as future sales, the impact, length and severity of the COVID-19 pandemic, general economic recovery from the effects of the COVID-19 pandemic, and the adequacy of the actions taken in response to the pandemic, which involve a number of risks and uncertainties, including but not limited to those discussed in the “Risk Factors” section contained in Item 1A in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 24, 2022, and the following risks and uncertainties: the negative impact that the COVID-19 pandemic has already had, and may continue to have, on the Company’s business and financial condition; the impact on the global economy and supply chains of the ongoing military conflict in Ukraine and the sanctions related thereto; the Company’s ability to maintain and expand its revenue streams to compensate for the lower demand for the Company’s digital cinema products and installation services; potential interruptions of supplier relationships or higher prices charged by suppliers; the Company’s ability to successfully compete and introduce enhancements and new features that achieve market acceptance and that keep pace with technological developments; the Company’s ability to successfully execute its capital allocation strategy or achieve the returns it expects from these investments; the Company’s ability to maintain its brand and reputation and retain or replace its significant customers; challenges associated with the Company’s long sales cycles; the impact of a challenging global economic environment or a downturn in the markets (such as the current economic disruption and market volatility generated by the ongoing COVID-19 pandemic and ongoing military conflict in Ukraine and related sanctions); economic and political risks of selling products in foreign countries (including tariffs); risks of non-compliance with U.S. and foreign laws and regulations, potential sales tax collections and claims for uncollected amounts; cybersecurity risks and risks of damage and interruptions of information technology systems; the Company’s ability to retain key members of management and successfully integrate new executives; the Company’s ability to complete acquisitions, strategic investments, entry into new lines of business, divestitures, mergers or other transactions on acceptable terms, or at all; the impact of the COVID-19 pandemic on the Company’s portfolio companies; the Company’s ability to utilize or assert its intellectual property rights, the impact of natural disasters and other catastrophic events (such as the ongoing COVID-19 pandemic and ongoing military conflict in Ukraine and related sanctions); the adequacy of insurance; the impact of having a controlling stockholder and vulnerability to fluctuation in the Company’s stock price. Given the risks and uncertainties, readers should not place undue reliance on any forward-looking statement and should recognize that the statements are predictions of future results which may not occur as anticipated. Many of the risks listed above have been, and may further be, exacerbated by the ongoing COVID-19 pandemic, its impact on the cinema and entertainment industry, and the worsening economic environment. Actual results could differ materially from those anticipated in the forward-looking statements and from historical results, due to the risks and uncertainties described herein, as well as others not now anticipated. New risk factors emerge from time to time and it is not possible for management to predict all such risk factors, nor can it assess the impact of all such factors on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Except where required by law, the Company assumes no obligation to update, withdraw or revise any forward-looking statements to reflect actual results or changes in factors or assumptions affecting such forward-looking statements.

For Investor Relations Inquiries:

Mark Roberson, CEO	John Nesbett / Jennifer Belodeau
Ballantyne Strong, Inc.	IMS Investor Relations
704-994-8279	203-972-9200
[email protected]	[email protected]

IRVINE, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) — Today, ToughBuilt Industries, Inc. (“ToughBuilt”) (NASDAQ: TBLT; TBLTW) — has today announced major expansions to its network of storefronts in Great Britain, confirming broad new and expanding agreements with Huws Gray, Selco Builders Warehouse, MKM, City Electrical Factors, and Carpet & Flooring, magnifying the company’s online marketplace presence in Great Britain and representing more than 900 collective retail locations across the country.

Huws Gray is the United Kingdom’s largest independent builder’s merchant. Supplying materials to professional and DIY end users alike, it operates over 300 storefronts that trade under various brand names, including Huws Gray, Buildbase, The Timber Group, Civils & Lintels, and Frontline.

Additionally, ToughBuilt welcomes Selco Builder’s Warehouse, the UK’s fastest growing builder’s merchant, who distributes to construction professionals nationwide with a network of more than 73 outlets set to reach 100 locations by the end of 2026. As well as MKM, a building, timber, and plumbing supplies provider with more than 90 branches across England, Scotland, and Wales, and Carpet & Flooring, one of Britain’s largest flooring retailers and winner of the Contract Flooring Journal distributor of the year 3 years in a row.

ToughBuilt is also pleased to work with City Electrical Factors (CEF), the United Kingdom’s leading electrical wholesaler network. Beginning with a single storefront in Coventry in 1951, CEF has grown to more than 400 locations nationwide.

ToughBuilt CEO Michael Panosian stated, “ToughBuilt is growing rapidly in the United Kingdom, and we are pleased to expand our distribution network by nearly 900 storefronts across Great Britain. We are confident that this increased presence in the country will continue to grow our substantial market share and promote continued awareness of our brand’s commitment to premium quality products.”

ABOUT TOUGHBUILT INDUSTRIES, INC:
ToughBuilt is an advanced product design, manufacturer and distributor with emphasis on innovative products. Currently, we are focused on tools and other accessories for the professional and do-it-yourself construction industries. We market and distribute various home improvement and construction product lines for both the do-it-yourself and professional markets under the TOUGHBUILT brand name, within the global multibillion dollar per year tool market industry. All of our products are designed by our in-house design team. Since launching product sales in 2013, we have experienced significant annual sales growth. Our current product line includes three major categories, with several additional categories in various stages of development, consisting of Soft Goods & Kneepads and Sawhorses & Work Products. Our mission is to provide products to the building and home improvement communities that are innovative, of superior quality derived in part from enlightened creativity for our end users while enhancing performance, improving well-being and building high brand loyalty. Additional information about the Company is available at: https://www.toughbuilt.com/.

FORWARD-LOOKING STATEMENTS

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the impact of the worldwide COVID-19 pandemic and government actions, on our business, (ii) supply chain disruptions, (iii) market acceptance of our existing and new products, (iv) delays in bringing products to key markets, (v) an inability to secure regulatory approvals for the ability to sell our products in certain markets, (vi) intense competition in the industry from much larger, multinational companies, (v) product liability claims, (vii) product malfunctions, (viii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) our reliance on single suppliers for certain product components, (xi) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Investor Relations Contact:
KCSA Strategic Communications
David Hanover
[email protected]

Source: ToughBuilt Industries, Inc

 

Demodex blepharitis is a highly prevalent, yet often missed or misdiagnosed lid margin disease that impacts approximately 25 million eye care patients in the U.S.

IRVINE, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the launch of the “Look at the Lids” disease education campaign for Demodex blepharitis, a common lid margin disease that can negatively impact patients’ daily activities and eyelid health. The novel campaign is designed to encourage eye care professionals to screen for Demodex blepharitis in all eye care patients to identify and diagnose the disease sooner. The campaign will be unveiled at the 2022 American Academy of Ophthalmology (AAO) Annual Meeting in Chicago and the American Academy of Optometry (AAOpt) Annual Meeting in San Diego. “Look at the Lids” features real Demodex blepharitis patients and will include educational tools and resources for eye care professionals, including an informative website (www.LookattheLids.com), social media channels, webinars, launch events, and interactive activities at the Academy conferences.

“We’re thrilled to launch this truly unique disease education campaign for Demodex blepharitis, a pervasive and damaging eye disease that is commonly overlooked,” said Aziz Mottiwala, Chief Commercial Officer of Tarsus. “The goal of this campaign is to support eye care professionals so they can confidently and more frequently diagnose patients. Tarsus is committed to elevating eyelid health, and we look forward to bringing more awareness to this disease that negatively impacts so many patients.”

Approximately 25 million eye care patients in the United States have Demodex blepharitis, a lid margin disease characterized by eyelid inflammation, redness, and ocular irritation. The disease is caused by an infestation of Demodex mites, the most common ectoparasite found on humans. Collarettes, the cylindrical waxy debris composed of mite waste products and eggs on the eyelashes, are the pathognomonic sign of Demodex blepharitis, and can be identified by an eye care professional when a patient looks down during a slit lamp exam. One hundred percent of patients with collarettes have Demodex blepharitis.

“Demodex blepharitis, though extremely common, can masquerade as ocular allergies or dry eye disease since the symptoms are often similar,” said Eric Donnenfeld, MD, Cornea, Laser Cataract & Refractive Surgeon at OCLI Vision in New York. “The disease can be missed unless an eye care professional is specifically looking for the presence of collarettes, the sure sign of Demodex blepharitis. Fortunately, identifying collarettes is a simple step achieved by asking a patient to look down during a routine eye exam. I see Demodex in my practice daily, and I am encouraged that there is a campaign that will bring more visibility to this disease and assist other clinicians in their efforts to improve eyelid health.”

At both Academy meetings, “Look at the Lids” will have an interactive exhibit booth featuring a custom photo activation that allows eye care professionals to showcase their commitment to eyelid health by adding their own eyelid photo to a real-time updated video wall. The campaign will also feature launch events and interactive activities, all designed to provide disease education.

“It is remarkable how many patients I discover who have Demodex just by examining their lashes when they look down during a regular eye exam,” said Selina McGee, OD, FAAO, CEO of BeSpoke Vision in Oklahoma. “This disease is often hiding in plain sight, and without properly screening for it, many patients go undiagnosed. Demodex can cause damage and discomfort when left untreated, and I’m excited to be a part of a campaign designed to increase the identification and diagnosis of this very common disease.”

Eye care professionals can subscribe to the Collarette Coalition email list and be the first to receive the latest news and information on Demodex blepharitis at www.LookattheLids.com. The website also allows eye care professionals to submit their own photos and videos to the ‘Lid Gallery.’ Additionally, they can share their own Demodex blepharitis stories with the eye care community on social media by using #LookattheLids and following and tagging @lookatthelids on Instagram and Twitter.

In concert with the campaign – and as part of Tarsus’ commitment to education and innovation in eye care – the company will provide a donation to both the American Academy of Ophthalmology Foundation and the American Academy of Optometry Foundation.

About

Demodex

Blepharitis

Blepharitis is a common lid margin disease that is characterized by eyelid margin inflammation, redness and ocular irritation. Demodex blepharitis is caused by an infestation of Demodex mites, the most common ectoparasite found on humans and accounts for over two-thirds of all blepharitis cases. Demodex blepharitis may affect as many as 25 million Americans based on an extrapolation from the Titan study indicating 58% of patients presenting to U.S. eye care clinics have collarettes, a pathognomonic sign of Demodex infestation, and that at least 45 million people annually visit an eye care clinic. Demodex blepharitis can have a significant clinical burden and negative impact on patients’ daily lives. The Titan study also showed that current management tools, such as tea tree oil and lid wipes, are ineffective at treating Demodex blepharitis. Currently, there are no FDA-approved treatments for Demodex blepharitis.

About Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. Tarsus is studying two investigational medicines in clinical trials. Its lead product candidate, TP-03, is a novel therapeutic which has demonstrated positive results in two pivotal trials for the treatment of Demodex blepharitis, and of which a New Drug Application has been submitted to the U.S. Food & Drug Administration (FDA). TP-03 is also being developed for the treatment of Meibomian Gland Disease, and currently being studied in a Phase 2a clinical trial. In addition, Tarsus is developing TP-05, an oral, non-vaccine therapeutic for the prevention of Lyme disease, which is currently being studied in a Phase 1b clinical trial.

Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include statements regarding the potential market size for TP-03, future events and Tarsus’ plans for and the anticipated benefits of its product candidates including TP-03 and TP-05, the timing, objectives and results of the clinical trials, anticipated regulatory and development milestones, and the quotations of Tarsus’ management and consultants. The words, without limitation, “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would,” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Further, there are other risks and uncertainties that could cause actual results to differ from those set forth in the forward-looking statement and they are detailed from time to time in the reports Tarsus files with the Securities and Exchange Commission, including Tarsus’ Form 10-K for the year ended December 31, 2021 filed on March 14, 2022 and the most recent Form 10-Q quarterly filing filed with the SEC on August 11, 2022, each of which Tarsus incorporates by reference into this press release, copies of which are posted on its website and are available from Tarsus without charge. However, new risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Any forward-looking statements contained in this press release are based on the current expectations of Tarsus’ management team and speak only as of the date hereof, and Tarsus specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Contacts:

Media Contact:

Adrienne Kemp
Sr. Director, Corporate Communications
(949) 922-0801
[email protected]

Investor Contact:

David Nakasone
Head of Investor Relations
(949) 620-3223
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8a55faf1-5038-425d-85da-0325acdb2c0a

DENVER, Sept. 29, 2022 (GLOBE NEWSWIRE) — Assure Holdings Corp. (the “Company” or “Assure”) (NASDAQ: IONM), a provider of intraoperative neuromonitoring (“IONM”) and remote neurology services, announced that management will participate in the following investor conferences in October 2022:

• Roth Healthcare Opportunities Conference on October 6, 2022, in New York, NY. This invitation only event provides a forum for public healthcare companies to tell their stories to investors. The conference will consist of a 10-minute company presentation to the attendee audience, as well as one-on-one investor meetings.
• MicroCap Rodeo Windy City Roundup on October 12-13, 2022, in Chicago, IL. More than 60 microcap companies will meet with institutional investors, family offices and high net worth retail investors. Assure’s executive chairman and CEO John Farlinger is scheduled to present on October 12th at 12:00 p.m. ET with one-on-one meetings held throughout the conference. To receive additional information, request an invitation, or schedule a one-on-one meeting, please email [email protected].
• LD Micro Main Event on October 25-26, 2022, in Los Angeles, CA. The event will showcase over 200 small- and micro-cap companies. Assure’s CFO John Price is scheduled to present on October 26th at 3:30 p.m. ET with one-on-one meetings held throughout the conference.
• ThinkEquity Conference on October 26, 2022, in New York, NY. The ThinkEquity Conference brings together companies in the technology, healthcare, finance, and energy industries with institutional and accredited investors. Assure’s executive chairman and CEO John Farlinger is scheduled to present at 11:00 a.m. ET with one-on-one meetings held throughout the day.

Events with webcasted central presentations will be available live at https://ir.assureneuromonitoring.com/news-events/ir-calendar and available for replay after the live event.

About Assure Holdings

Assure Holdings Corp. is a best-in-class provider of outsourced intraoperative neuromonitoring and remote neurology services. The Company delivers a turnkey suite of clinical and operational services to support surgeons and medical facilities during invasive procedures that place the nervous system at risk including neurosurgery, spine, cardiovascular, orthopedic and ear, nose and throat surgeries. Assure employs highly trained technologists that provide a direct point of contact in the operating room. Physicians employed through Assure subsidiaries simultaneously monitor the functional integrity of patients’ neural structures throughout the procedure communicating in real-time with the surgeon and technologist. Accredited by The Joint Commission, Assure’s mission is to provide exceptional surgical care and a positive patient experience. For more information, visit the company’s website at www.assureneuromonitoring.com.

Forward-Looking Statements

This news release may contain “forward-looking statements” within the meaning of applicable securities laws, including, but not limited to comments with respect to: expectations with respect to the Company’s growth and development and the quality and results of future services. Forward-looking statements may generally be identified by the use of the words “anticipates,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “will,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to: the uncertainty surrounding the spread of COVID-19 and the impact it will have on the Company’s operations and business, its remote neurology business, and economic activity in general; and risks and uncertainties discussed in our most recent annual and quarterly reports filed with the United States Securities and Exchange Commission, including our annual report on Form 10-K filed on March 14, 2022, and available on the Company’s EDGAR profile at www.sec.gov, which risks and uncertainties are incorporated herein by reference. Except as required by law, Assure does not intend, and undertakes no obligation, to update any forward-looking statements to reflect, in particular, new information or future events.

Contact

Scott Kozak, Investor and Media Relations
Assure Holdings Corp.
1-720-617-2526
[email protected]

PRINCETON, N.J., Sept. 29, 2022 (GLOBE NEWSWIRE) — Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today issued its inaugural Environmental, Social and Governance (ESG) report. The report includes 2021 performance highlights in key areas such as employee health and safety, diversity and inclusion, community impact, ethics and compliance, and environmental responsibility. The report also includes the company’s ESG strategy and roadmap to long-term sustainability.

“Our company purpose and values have long guided our global sustainability priorities, and we have a deeply entrenched ESG mindset and culture. Building sustainable organizations not only makes business sense, but it also is the right thing to do,” said Jan De Witte, president and chief executive officer, Integra LifeSciences. “Every day, Integra colleagues deliver lifesaving and life-enhancing products and technologies to our customers and fulfill our responsibility to preserve the health of patients and the planet.”

Highlights of the report include:

• Identification and ranking of our top 12 ESG priorities based on feedback from internal and external stakeholders;
• Expansion of board oversight to formally include ESG strategy, stakeholder engagement and reporting;
• An update on our diversity and inclusion efforts, which include an increase in the number of employee resource groups and the advancement of women in leadership positions;
• A description of our environmental, health, safety, and security policies and governance structure, including the digitization of our EHS management systems; and
• The calculation of our direct greenhouse gas emissions and a commitment to setting concrete reduction targets in the near future.

Integra prepared this ESG report in alignment with several external guidelines and measurement frameworks, including the Global Reporting Index and the Sustainability Accounting Standards Board Index.

Read the full Integra ESG Report here.

About Integra LifeSciences

Integra LifeSciences is a global leader in regenerative tissue technologies and neurosurgical solutions dedicated to limiting uncertainty for clinicians so they can focus on providing the best patient care. Integra offers a comprehensive portfolio of high quality, leadership brands that include AmnioExcel^®, Aurora^®, Bactiseal^®, BioD™, CerebroFlo^®, CereLink^® Certas^® Plus, Codman^®, CUSA^®, Cytal^®, DuraGen^®, DuraSeal^®, Gentrix^®, ICP Express^®, Integra^®, Licox^® , MAYFIELD^®, MediHoney^®, MicroFrance^®, MicroMatrix^®, NeuraGen^®, NeuraWrap^™, PriMatrix^®, SurgiMend^®, TCC-EZ^® and VersaTru^®. For the latest news and information about Integra and its products, please visit www.integralife.com.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties and reflect the Company’s judgment as of the date of this release. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. These risks and uncertainties include market conditions and other factors beyond the Company’s control and the economic, competitive, governmental, technological, and other factors identified under the heading “Risk Factors” included in item 1A of Integra’s Annual Report on Form 10-K for the year ended December 31, 2021, and information contained in subsequent filings with the Securities and Exchange Commission. These forward-looking statements are made only as the date thereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:

Investors:


Chris Ward
(609) 936-2322
[email protected]

Media:


Laurene Isip
(609) 208-8121
[email protected]

LOS ANGELES, Sept. 29, 2022 (GLOBE NEWSWIRE) — via InvestorWire – Freight Technologies Inc. (NASDAQ: FRGT), a technology company that develops solutions to optimize and automate the supply chain process, today announces it has selected the corporate communications expertise of IBN, a multifaceted financial news and publishing company for private and public entities.

Freight Technologies provides a platform (Fr8App) for B2B cross-border shipping and domestic shipping within the United States-Mexico-Canada (NAFTA) region. The company’s mission is to revolutionize cross-border shipping by providing carriers with increased growth opportunities and shippers with flexibility, visibility and simplicity for the once-complex process of international over-the-road shipping. Freight Technologies leverages artificial intelligence to provide cloud-based platforms aimed at automating the over-the-road transportation process, effectively reducing human touch points and expediting load booking times.

The company’s suite of solutions includes:

• 
  
  Fr8app
  
  – A B2B marketplace powered by AI and machine learning offering a real-time broker portal to connect shippers with qualified carriers
• Fr8Radar – A tracking solution providing shippers and carriers real-time locational data via Fr8app’s mobile solution or through integration with third-party GPS alternatives
• Fr8TMS – A transportation management system designed to help shippers manage their freight and all of the documents involved in shipping transactions, including invoices, customs documents, confirmation rates and proof of deliveries
• Fr8FMS – A fleet management system allowing transportation companies to better manage their fleets, reduce operational costs and provide better service to their customers
• Fr8Data – A data solution offering real-time dashboards and reports to shippers and carriers in an effort to increase visibility and control while supporting better business decisions
• Fr8Fleet – A platform that provides private fleet management, enabling large corporate shippers to purchase dedicated capacity secured by Fr8app in exchange for a fixed fee

As part of the Client Partner relationship, IBN will leverage its investor based distribution network of 5,000+ key syndication outlets, various newsletters, social media channels, wire services via InvestorWire, blogs and other outreach tools to generate greater awareness for Freight Technologies.

With 15+ years of experience assisting 500+ client partners improve communications within the investment community, and a sizable family of 50+ trusted brands, IBN has amassed a collective audience that includes millions of social media followers. IBN is uniquely positioned to provide Freight Technologies the solutions needed to reach a wide audience of investors, consumers, journalists and the general public.

“Thousands of legacy brokers, tens of thousands of shippers and hundreds of thousands of carriers still rely on outdated systems to arrange transport. Through Fr8app, Freight Technologies is leveraging AI and machine learning to connect shippers with qualified carriers in real time,” states Chris Johnson, Director of Client Solutions for IBN. “We’re excited to customize our comprehensive suite of corporate communications solutions for Freight Technologies as it works to improve the efficiency and sustainability of cross-border shipping across North America.”

To learn more about Freight Technologies, please visit the company’s corporate newsroom @ www.IBN.fm/FRGT

About Freight Technologies Inc.

Freight Technologies is a technology company developing solutions to optimize and automate the supply chain process. Its wholly owned subsidiary, Freight App Inc. (Fr8app), is a B2B cross-border shipping marketplace in the NAFTA region powered by AI and machine learning. Focused on making shipping transparent and efficient, Fr8app provides carriers with increased growth opportunities and shippers with flexibility, visibility and simplicity for the once-complex process of international over-the-road (OTR) shipping. Fr8app uses its proprietary technology platform to connect carriers and shippers and significantly improve matching and operation efficiency via innovative technologies such as live pricing and real-time tracking, digital freight marketplace, broker, transportation management, fleet management and committed capacity solutions. The company is headquartered in Houston, Texas. For more information, visit the company’s website at www.Fr8Technologies.com

About IBN

IBN
consists of financial brands introduced to the investment public over the course of 15+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through NetworkNewsWire (“NNW”) and its Investor Brand Platform, IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Fr8Tech Contact:

[email protected]

Corporate Communications

IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

CAMBRIDGE, Mass., Sept. 29, 2022 (GLOBE NEWSWIRE) — Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the accelerated approval of SRP-9001 (delandistrogene moxeparvovec) to treat ambulant patients with Duchenne muscular dystrophy. SRP-9001 is an investigational gene therapy for Duchenne being developed in partnership with Roche.

The BLA is submitted for accelerated approval based on the expression of SRP-9001 dystrophin protein, an internally shortened and functional version of dystrophin, as a surrogate endpoint reasonably likely to predict clinical benefit. Among other things, the BLA is based on positive pre-clinical, biomarker and clinical functional results. In clinical trials, SRP-9001 demonstrated positive results at multiple time points, including one-, two- and four-years after treatment, in addition to a consistent safety profile. The submitted BLA for SRP-9001 includes efficacy and safety data from Studies SRP-9001-101, SRP-9001-102, SRP-9001-103 (also known as ENDEAVOR), as well as an integrated analysis across these three clinical studies comparing functional results to a propensity-score-matched external control (EC). Quantification of the SRP-9001-protein expression is measured by western blot and supported by immunofluorescence and efficacy is further supported by biomarker and clinical functional benefit as measured by the North Star Ambulatory Assessment (NSAA) and secondary timed tests.

Sarepta has proposed its fully-enrolled study EMBARK (Study SRP-9001-301) as the post-marketing confirmatory study to support the accelerated approval. EMBARK is a global, randomized, double-blind, placebo-controlled clinical trial. The primary endpoint for EMBARK is the assessment of the change in NSAA total score from baseline to week 52 compared to placebo.

“Every hour of every day, this ruthless disease, Duchenne, robs thousands of children in the United States of muscle as it steals their future from them. Sarepta’s BLA submission for an accelerated approval of SRP-9001 is a significant milestone in our quest to intervene with urgency on behalf of the children we serve,” said Doug Ingram, president and chief executive officer, Sarepta Therapeutics. “If approved, SRP-9001 will be the first gene therapy available for Duchenne patients. We are enormously grateful to the courageous families who have participated in the SRP-9001 trials and to the participating clinical investigators and experts who have guided us and played a crucial part in reaching this milestone.”

SRP-9001 was granted Fast Track designation in July 2020, an FDA process designed to facilitate the development and expedited review of therapies that treat serious conditions and fill unmet medical needs. In addition to Fast Track, SRP-9001 has also been granted Rare Pediatric Disease (RPD) designation in the United States, and Orphan Drug status in the United States, the European Union, Switzerland and Japan.

About SRP-9001 (delandistrogene moxeparvovec)


SRP-9001 (delandistrogene moxeparvovec) is an investigational gene transfer therapy intended to deliver SRP-9001 to muscle tissue for the targeted production of functional components of dystrophin. Sarepta is responsible for global development and manufacturing for SRP-9001 and plans to commercialize SRP-9001 in the United States upon receiving FDA approval. In December 2019, Roche partnered with Sarepta to combine Roche’s global reach, commercial presence and regulatory expertise with Sarepta’s gene therapy candidate for Duchenne to accelerate access to SRP-9001 for patients outside the United States.

About Duchenne Muscular Dystrophy


Duchenne muscular dystrophy (DMD) is a rare, fatal neuromuscular genetic disease that occurs in approximately one in every 3,500-5,000 newborn males worldwide. DMD is caused by a change or mutation in the gene that encodes instructions for dystrophin. Symptoms of DMD usually appear in infants and toddlers. Affected children may experience developmental delays such as difficulty in walking, climbing stairs or standing from a sitting position. As the disease progresses, muscle weakness in the lower limbs spreads to the arms and other areas. Most patients require full-time use of a wheelchair in their early teens, and then progressively lose the ability to independently perform activities of daily living such as using the restroom, bathing and feeding. Eventually, increasing difficulty in breathing due to respiratory muscle dysfunction requires ventilation support, and cardiac dysfunction can lead to heart failure. The condition is universally fatal, and patients usually succumb to the disease in their twenties.

About Sarepta Therapeutics


Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on Twitter, LinkedIn, Instagram and Facebook.

Internet Posting of Information


We routinely post information that may be important to investors in the ‘For Investors’ section of our website at 


www.sarepta.com


. We encourage investors and potential investors to consult our website regularly for important information about us.

Forward-Looking Statements


This press release contains “forward-looking statements.” Any statements that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “believe,” “anticipate,” “plan,” “expect,” “will,” “may,” “intend,” “prepare,” “look,” “potential,” “possible” and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements relating to the benefits of SRP-9001; the potential for SRP-9001 to be the first approved gene therapy for Duchenne
available to the majority of those with Duchenne;
our expectation to use our
fully-enrolled study EMBARK (Study SRP-9001-301) as the post-
marketing
confirmatory study to support the accelerated approval
and our quest to intervene with urgency on behalf of the children we serve.

These forward-looking statements involve risks and uncertainties, many of which are beyond our control. Known risk factors include, among others: the possible impact of regulations and regulatory decisions by the FDA and other regulatory agencies on our business, as well as the development of our product candidates and our financial and contractual obligations; that we may not be able to execute on our business plans and goals, including meeting our expected or planned regulatory milestones and timelines, clinical development plans, and bringing our product candidates to market, due to a variety of reasons, some of which may be outside of our control, including possible limitations of company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, regulatory, court or agency decisions, such as decisions by the United States Patent and Trademark Office with respect to patents that cover our product candidates, and the COVID-19 pandemic; success in pre-clinical trials and early clinical trials, especially if based on a small patient sample, does not ensure that later clinical trials will be successful; different methodologies, assumptions and applications we use to assess particular safety or efficacy parameters may yield different statistical results, and even if we believe the data collected from clinical trials of our product candidates are positive, these data may not be sufficient to support approval by the FDA or other global regulatory authorities; and those risks identified under the heading “Risk Factors” in Sarepta’s most recent Annual Report on Form 10-K for the year ended December 31, 2021, and most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company which you are encouraged to review.

Any of the foregoing risks could materially and adversely affect the Company’s business, results of operations and the trading price of Sarepta’s common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the SEC filings made by Sarepta. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except as required by law.

Source: Sarepta Therapeutics, Inc.

Investor Contact:


Ian Estepan, 617-274-4052
[email protected]

Media Contact:


Tracy Sorrentino, 617-301-8566
[email protected]

EL SEGUNDO, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) — As US auto sales are forecasted to be majority EV by 2030, Navitas Semiconductor (Nasdaq: NVTS), the only pure-play, next-generation power semiconductor company, will showcase industry-leading gallium nitride (GaN) and silicon carbide (SiC) technologies at the IEEE Energy Conversion Congress & Expo (ECCE) in Detroit, Michigan (October 9^th-13^th).ⁱ

ECCE 2022 features both industry-driven and application-oriented technical sessions, as well as industry expositions and seminars in electrical and electromechanical energy conversion. It provides engineers, researchers, and professionals a perfect blend of state-of-the-art, technical prowess and commercial opportunities.

Navitas’ 650 V-rated GaNFast power ICs with GaNSense™ technology are optimized for the broad range of 400 V-rated EV battery applications and AC-interfacing. New Navitas GeneSiC 1200 V FETs and diodes address 800 V-rail applications for higher-power trucks, buses, and performance passenger cars. Navitas’ unique EV System Design Center provides complete platform designs to accelerate time-to-market, including a 3-in-1 800 V-rated bi-directional charger and DC-DC converter, with up to 18% weight savings, up to 20% energy savings, and up to 65% faster charging than competing solutions.

“Upgrading from legacy silicon to GaN and SiC accelerates EV adoption by two years,” said Llew Vaughan-Edmunds, senior director of marketing at Navitas Semiconductor. “ECCE is a critical forum for professionals working to optimize power conversion across the EV landscape, and a fertile environment for detailed discussions on new technology adoption.”

ECCE 2022 is at Huntington Place, 1 Washington Blvd., Detroit, MI 48226. Navitas will feature in a focus session on SiC and GaN applications in EV from 12.30 pm to 2.10 pm (EDT) on Monday 10^th October.

To meet with Navitas at ECCE, please contact [email protected].

About Navitas

Navitas Semiconductor (Nasdaq: NVTS), founded in 2014, is the only pure-play, next-generation power-semiconductor company (and industry leader in GaN power ICs and SiC technology). GaNFast™ power ICs integrate gallium nitride (GaN) power and drive, with control, sensing, and protection to enable faster charging, higher power density, and greater energy savings. Complementary GeneSiC™ power devices are optimized high-power, high-voltage, and high-reliability silicon carbide (SiC) solutions. Focus markets include mobile, consumer, data center, EV, solar, wind, smart grid, and industrial. Over 185 Navitas patents are issued or pending. Over 50 million GaN units have been shipped to customers including Samsung, Dell, Lenovo, and Xiaomi, with zero reported GaN field failures. Navitas introduced the industry’s first and only 20-year warranty. Navitas is the world’s first semiconductor company to be CarbonNeutral^®-certified.

Navitas Semiconductor, GaNFast, GaNSense, GeneSiC, and the Navitas logo are trademarks or registered trademarks of Navitas Semiconductor Limited. All other brands, product names, and marks are or may be trademarks or registered trademarks used to identify products or services of their respective owners.

Contact Information:

Stephen Oliver, VP Corporate Marketing & Investor Relations, [email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f5e481b2-5939-41cb-a3d0-ad041d8ce900

HERZLIYA, Israel, Sept. 29, 2022 (GLOBE NEWSWIRE) — Safe-T Group Ltd. (NASDAQ: SFET) (TASE: SFET) (“Safe-T” or the “Company”), a global provider of cybersecurity and privacy solutions to consumers and enterprises, today announced that its Apple iOS privacy application is ranking among the top ten privacy applications (category: productivity) in the U.S. App Store.

App Store ranks are determined by keyword and metadata optimization. Additional factors include user reviews, application performance, click-through rate (CTR), marketing, productivity and more.

Safe-T’s Consumer Privacy solution provides users with a robust privacy protection tool. Utilizing advanced encryption technologies, the privacy solution prevents access to and monitoring of a user’s personal data. By blocking the ability to track or monitor a user’s online and historical activity, their personal information remains private. The application is currently available for Android, Apple iOS, and Windows personal computer users.

“We are pleased with the traction our privacy application is gaining from iOS users and are extremely proud to have our first application ranked high among the strongest brands in this space within such a short time following its launch,” commented Shachar Daniel, Chief Executive Officer of Safe-T. “We intend to continue to invest in our technology to provide the best solutions to our current and future customers and increase our high-margin growth in recurring revenue.”

About Safe-T® Group Ltd.

Safe-T Group Ltd. (Nasdaq, TASE: SFET) is a global provider of cyber-security and privacy solutions to consumers and enterprises. The Company operates in three distinct segments, tailoring solutions according to specific needs. The segments include, enterprise cyber-security solutions, enterprise privacy solutions, and consumer cyber-security and privacy solutions.

Our cyber-security and privacy solutions for consumers provide a wide security blanket against ransomware, viruses, phishing, and other online threats, as well as a powerful, secured, and encrypted connection, masking their online activity and keeping them safe from hackers. The solutions are designed for both advanced and basic users, ensuring full protection for all personal and digital information.

Our privacy solutions for enterprises are based on our advanced and secured proxy network, the world’s fastest, enabling our customers to collect data anonymously at any scale from any public sources over the web using a unique hybrid network. Our network is the only one of its kind that is comprised of millions of residential exit points based on our proprietary reflection technology and hundreds of servers located at our ISP partners around the world. The infrastructure is optimally designed to guarantee the privacy, quality, stability, and the speed of the service.

Our cyber-security solutions for enterprises, designed for cloud, on-premises, and hybrid networks, mitigates attacks on enterprises’ business-critical services and sensitive data, while ensuring uninterrupted business continuity. Organizational data access, storage, and exchange use cases, from outside the organization or within, are secured according to the “validate first, access later” philosophy of Safe-T’s zero trust. Our ZoneZero® solutions are available by our reseller, TerraZone Ltd., a global information security provider, as a solution or cloud service.

For more information about Safe-T, visit www.safetgroup.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, Safe-T is using forward-looking statements in this press release when it discusses the benefits of its Consumer Privacy solution and its potential to address market need and/or demand, its intention to continue to invest in its technology to provide the best solutions to its current and future customers, and intention to increase high-margin growth in recurring revenue. Because such statements deal with future events and are based on Safe-T’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Safe-T could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in Safe-T’s annual report on Form 20-F filed with the Securities and Exchange Commission (“SEC”) on March 29, 2022, and in any subsequent filings with the SEC. Except as otherwise required by law, Safe-T undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Safe-T is not responsible for the contents of third-party websites.

INVESTOR RELATIONS CONTACTS:

Steve Gersten, Director of Investor Relations
Safe-T Group Ltd.
813-334-9745
[email protected]

Michal Efraty
Investor Relations, Israel
+972-(0)52-3044404
[email protected]

• Randomized, controlled clinical trial data on advanced dry eye patients from the OLYMPIA trial recently published in Clinical Ophthalmology
• Study authors concluded that the TearCare procedure delivered superior symptoms improvements over LipiFlow in patients suffering from advanced dry eye disease. These patients experienced significantly better symptoms improvements, quality of vision, and symptom frequency

MENLO PARK, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives today announced Clinical Ophthalmology has published data from a subgroup analysis of the OLYMPIA trial, which showed a single treatment with the TearCare System led to superior symptoms relief across the following primary symptoms endpoints (Ocular Surface Disease Index – OSDI, Symptom Assessment in Dry Eye – SANDE, Eye Dryness – ED) compared to a LipiFlow application in patients with more severe forms of DED due to meibomian gland dysfunction (MGD).¹

“Since obstruction of the meibomian glands is the underlying cause of MGD or evaporative dry eye, thorough and comprehensive clearance of the obstruction and the restoration of gland health and meibum production is the preferred treatment. There are different technologies available to address MGD and the unique technological design and procedural differences will naturally impact clinical outcomes and success rates. OLYMPIA demonstrated that the differentiated TearCare technology delivers differentiated clinical outcomes,” said Preeya K. Gupta, M.D., Managing Director of Triangle Eye Consultants, Raleigh, N.C. and first author on the published OLYMPIA study. “We are pleased to see that not only was TearCare able to show a clinically meaningful benefit across all DED patients regardless of severity of disease, but it also demonstrated superior symptoms outcomes among those dry eye patients with advanced disease. The subgroup analysis within OLYMPIA confirms the consistently strong clinical outcomes that many clinicians and I are seeing in our dry eye patients treated with the TearCare System.”

The OLYMPIA study was a multicenter, masked, randomized controlled trial in which 235 participants received either a single TearCare treatment (n = 115) or a single LipiFlow treatment (n = 120) and were followed for one-month post-treatment. Signs and symptoms were assessed across widely accepted endpoints, including the Ocular Surface Disease Index (OSDI), Symptom Assessment in Dry Eye (SANDE), Tear Breakup Time (TBUT) and Eye Dryness (ED) questionnaires at baseline and at one month. At one month, both treatments demonstrated a statistically significant improvement in all primary and secondary endpoints.²

In the subset of more severe patients (MGSS <7) with similar OSDI baseline, those receiving TearCare treatment (n=56) achieved an OSDI score reduction of -31.0 versus -21.4 for those that received LipiFlow treatment (n=65), a statistically significant difference in OSDI symptoms improvements in favor of TearCare. The mean reduction from baseline in SANDE frequency scores also favored a TearCare reduction of 51.9 versus LipiFlow’ s 41.5, another statistically significant difference in favor of TearCare. In evaluation of the Eye Dryness Scores within this more severe subgroup, the authors reported the treatment effect of TearCare also trended in favor of TearCare with a mean ED score difference of 8.9 (p=0.071) when compared to LipiFlow.

“As payors evaluate appropriate coverage and reimbursement for select MGD treatments, like TearCare, that are being rigorously clinically evaluated through thoughtfully designed RCTs like OLYMPIA (TearCare/device vs LipiFlow/device) and Sahara (TearCare/device vs Restasis/drug), our patients currently paying out of pocket for heat and expression MGD treatment have high expectations for noticeable improvement,” said Marc Bloomenstein, O.D., Schwartz Laser Center. “The evidence provided in this OLYMPIA subgroup analysis reinforces my confidence in TearCare as my MGD treatment of choice across all patient populations, including the more challenging advanced dry eye patients. Hopefully these study results will encourage my colleagues to establish proficiency in meibomian gland expression following the delivery of therapeutic heat delivery to the eyelids.”

“We are encouraged by the superior clinical findings in this subgroup analysis of advanced dry eye patients from the OLYMPIA trial,” said Paul Badawi, CEO of Sight Sciences. “TearCare’s intuitive design enables clinicians to thoroughly and comprehensively address the root causes of the signs and symptoms of dry eye due to MGD and these data further confirm our confidence in the clinical and economic value that TearCare brings to patients, providers and payors. On the heels of the publication of this superior symptoms data from OLYMPIA, we also announced the completion of patient enrollment in Sahara, our second major RCT where we are comparing TearCare to the standard of care in dry eye, Restasis. We look forward to the readout of TearCare (device) vs Restasis (drug) in the summer of 2023.”

* LipiFlow is a trademark of Johnson & Johnson

References:

1. Holland EJ, Loh J, Bloomenstein M, et al. A comparison of TearCare and LipiFlow systems in reducing dry eye disease symptoms associated with meibomian gland disease. Clin Ophthalmol. 2022; 16:2861-2871. doi:10.2147/OPTH.S368319

2. Gupta PK, Holland EJ, Hovanesian J, et al. TearCare for the treatment of meibomian gland dysfunction in adult patients with dry eye disease: a masked randomized controlled trial. Cornea. 2022;41(4):417-426. doi:10.1097/ICO.0000000000002837

About Sight Sciences

Sight Sciences is an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI^® Surgical System is a minimally invasive glaucoma surgery (MIGS) device indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma (POAG), the world’s leading cause of irreversible blindness. The Company’s TearCare^® System is 510(k) cleared for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), enabling office-based clearance of gland obstructions by an eye care professional to address the leading cause of dry eye disease. For more information, visit www.sightsciences.com.

About the TearCare® System

The TearCare System is FDA cleared and indicated for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction, when used in conjunction with manual expression of the meibomian glands.

The TearCare System is the only device designed to evacuate obstructed meibomian glands while harnessing a natural blink experience. The system is comprised of single-use, universally fitting SmartLids™ which are placed on the eyelids to deliver “intelligent therapeutic heat” safely and effectively. The portable SmartHub™ communicates directly with the SmartLids to precisely control the amount of phase transition heating and the duration of treatment. After 15 minutes of therapeutic heat, the Clearance Assistant forceps allows the ECP to control expression of the stagnant, obstructed meibum expertly and precisely by targeting individual meibomian glands while obtaining full visual confirmation of the success of this personalized treatment.

Forward-Looking Statements 
This press release, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and includes this statement for purposes of complying with these safe harbor provisions. Any statements made in this press release or during the earnings call that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include information concerning possible or assumed future results of operations, including descriptions of our business plan and strategies. These statements often include words such as “anticipate,” “expect,” “suggests,” “plan,” “believe,” “intend,” “estimates,” “targets,” “projects,” “should,” “could,” “would,” “may,” “will,” “forecast” and other similar expressions. We base these forward-looking statements on our current expectations, plans and assumptions that we have made in light of our experience in the industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate under the circumstances at such time. Although we believe that these forward-looking statements are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our business, results of operations and financial condition and could cause actual results to differ materially from those expressed in the forward-looking statements. These statements are not guarantees of future performance or results. The forward-looking statements are subject to and involve risks, uncertainties and assumptions, and you should not place undue reliance on these forward-looking statements. These forward-looking statements include, but are not limited to, statements concerning the following: estimates of our total addressable market, future revenue, expenses, capital requirements, and our needs for additional financing; our ability to enter into and compete in new markets; execution of our market strategies; the impact of the COVID-19 pandemic on our business, our customers’ and suppliers’ businesses and the general economy; our ability to compete effectively with existing competitors and new market entrants; our ability to scale our infrastructure; our ability to manage and grow our business by expanding our sales to existing customers or introducing our products to new customers; our ability to establish and maintain intellectual property protection for our products or avoid claims of infringement; potential effects of extensive government regulation; our abilities to obtain and maintain regulatory approvals and clearances for our products that support our revenue projections, business strategies and growth; our ability to successfully execute our clinical trial roadmap; our ability to obtain and maintain sufficient reimbursement for our products; our abilities to protect and scale our intellectual property portfolio; our ability to hire and retain key personnel; our ability to obtain financing in future offerings; the volatility of the trading price of our common stock; our expectation regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups Act (the “JOBS Act”); our ability to maintain proper and effective internal controls; and the other important factors discussed under the caption “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, as may be updated from time to time in subsequent filings. These cautionary statements should not be construed by you to be exhaustive and are made only as of the date of this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.   

Media contact 
Holly Yarbrough
RHMM Inc.
[email protected] 

Investor contact 
Philip Taylor 
Gilmartin Group 
415.937.5406 
[email protected]